Is SS-31 from Lumera Labs HPLC verified?

Yes. Every SS-31 lot Lumera Labs ships is HPLC-purity tested at synthesis and retested by Janoshik Analytical before release. The lot-specific Certificate of Analysis is published on the Lab Results page.

Is SS-31 sold for human use?

No. SS-31 is sold strictly as a laboratory reference standard for in-vitro research. It is not approved by Health Canada or the FDA for human use. Every order requires a research-use declaration.

How is SS-31 shipped?

SS-31 is lyophilized at synthesis, sealed under nitrogen, and shipped from Kelowna, BC at -20 C through cold-chain insulated packaging via Canada Post Xpresspost. Free shipping over $200 CAD. 24-48h transit Canada-wide.

Where can I see the COA for SS-31?

Each shipment includes a lot-specific Certificate of Analysis. The current lot's COA is also published at https://lumerapeptide.com/lab-results/ and can be cross-referenced by the batch number printed on each vial.

4.7 · 98 researcher reviews

Longevity · Mitochondrial-targeted peptide

SS-31

SKU LUM-SS31-10 · C₃₂H₄₉N₉O₅ · 639.79 g/mol · CAS 736992-21-5

A cell-permeable mitochondria-targeted tetrapeptide that selectively binds cardiolipin and reduces mitochondrial reactive-oxygen-species generation.

Purity (HPLC): ≥ 99.15%
Net peptide: 5.00 mg ± 2%
Endotoxin: < 0.5 EU/mg
Format: Lyophilized vial
Storage: −20 °C, desiccated
Shelf life: 24 months from MFG

$140CAD / 10 mg vial

In stock · Lot 26-A031

Qty

Bulk 10+: $24 / vial

Add $200 for free cold-chain shipping

HPLC + MS verified per lot
Cold-chain to your door
COA bundled with shipment
Lot retains kept 5 years

Overview

SS-31 (elamipretide) is a cell-permeable synthetic tetrapeptide that concentrates 1000-fold inside the inner mitochondrial membrane via cardiolipin binding. The peptide stabilizes cardiolipin in the cristae, supporting electron-transport-chain assembly and reducing reactive-oxygen-species leak.

Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped cold-chain at −20 °C from our Kelowna facility.

Research applications

Mitochondrial cardiolipin-binding assays, ETC supercomplex assembly investigations, ischemia-reperfusion in-vitro models, and bioenergetic profiling of aged or stressed cell lines.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

Parameter	Value
Sequence	D-Arg-Dmt-Lys-Phe-NH₂
Molecular formula	C₃₂H₄₉N₉O₅
Molecular weight	639.79 g/mol
CAS number	736992-21-5
Length	4 residues (cell-permeable)

Quality

Test	Specification
HPLC purity	≥ 99.0% (lot LM-2659: 99.18%)
Mass confirmation	ESI-MS within 0.5 Da
Net peptide content	≥ 80% by AAA
Endotoxin	< 0.5 EU/mg (LAL)
Bioburden	< 10 CFU/g
Residual TFA	< 1.0%

Lot LM-2659

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

Method	Result
RP-HPLC at 220 nm	99.18% main peak
ESI-MS (positive)	639.8 Da (theor. 639.79)
Amino acid analysis	82.1% net peptide
LAL endotoxin	< 0.05 EU/mg
Karl Fischer (water)	2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029–2050.

Birk AV et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria. J Am Soc Nephrol. 2013;24(8):1250–1261.

Mitchell W et al. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics. J Biol Chem. 2020;295(21):7452–7469.

Citing this material

SS-31 reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-SS31-10, Lot 26-A031.

Related · Longevity axis

Often paired in studies.

View catalog →

GLP-1/GIP · Metabolic

Tirzepatide

10 mg · ≥ 99.3%

$40 CADView →

Tri-agonist · Metabolic

Retatrutide

10 mg · ≥ 99.2%

$85 CADView →

Metabolic

Cagrisema

10 mg · ≥ 99.1%

$72 CADView →

Growth axis

AOD-9604

10 mg · ≥ 99.0%

$36 CADView →

Why Lumera

Janoshik Analytical HPLC ≥ 99.15% on this lot
LC-MS identity confirmed before release
LAL endotoxin below detection limit
Cold-chain shipped −20°C from Kelowna, BC

Background research

What the literature says about Ss 31.

Mechanism

Ss 31 is a mitochondrial-targeted peptide, classified within the cardiolipin protection pathway. Structurally it is a tetrapeptide D-Arg-2',6'-Dmt-Lys-Phe-NH₂. SS-31 (elamipretide) is a mitochondrially-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane. Szeto and Birk (2014) characterized its protective effect on mitochondrial structure and function.

In an in-vitro setting, Ss 31 interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.

Common research applications

In-vitro receptor-binding and dose-response screens against the cardiolipin protection target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Ss 31's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.

Storage & handling

Ss 31 arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.

References

Szeto HH, Birk AV. Clin Pharmacol Ther. 2014;96(6):672-83.
Karaa A et al. Neurology. 2018;90(14):e1212-21.
Birk AV et al. J Am Soc Nephrol. 2013;24(8):1250-61.

For laboratory research only. Ss 31 is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.